Search - tctmd.com

Displaying 121 - 140 of 148

Sort: Relevancy | Date

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

DAPT Analysis Eases Concerns Over Slightly Higher Death Rate Seen With Extended Thienopyridine Use

Caitlin E. Cox

September 01, 2015

Presentation ESC 2015

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Presenter: Jacob A. Udell

August 31, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2015

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2014

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

Todd Neale

September 02, 2014

News Conference News ESC 2014

ATLANTIC: Prehospital Ticagrelor Safe in STEMI, But No Added Benefit Compared With In-Hospital Administration

Yael L. Maxwell

September 01, 2014

News Conference News ESC 2013

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

September 09, 2013

News Conference News ESC 2013

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Yael L. Maxwell

September 03, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

News Conference News ESC 2013

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

Yael L. Maxwell

September 01, 2013

News Conference News ESC 2012

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Caitlin E. Cox

September 04, 2012

Presentation ESC 2012

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Presenter: Willem Dewilde

August 28, 2012

News Conference News ESC 2012

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Yael L. Maxwell

August 28, 2012

Presentation ESC 2012

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial

Presenter: Matthew Roe

August 28, 2012

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

Presentation ESC 2012

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

Presenter: 159942|Jolanta Siller-Matula

August 26, 2012

Advertisement

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

DAPT Analysis Eases Concerns Over Slightly Higher Death Rate Seen With Extended Thienopyridine Use

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

ATLANTIC: Prehospital Ticagrelor Safe in STEMI, But No Added Benefit Compared With In-Hospital Administration

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content